Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.


Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in Care

Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in Care

Sunday, June 4, 2017
7:00 PM - 9:00 PM

Dinner and registration: 6:30 PM – 7:00 PM

Hilton Chicago
International Ballroom South (Lobby Level)
720 S Michigan Avenue
Chicago, IL 60605


Optimizing treatment for patients with myeloproliferative neoplasms (MPNs) is challenging. There is a need for educational initiatives that provide clinicians with practical approaches that they can apply to maximize clinical benefits in patients they manage. A personalized approach to care in individual patients is key given that MPNs are heterogeneous with regard to their features, including prognosis, disease burden, symptoms, and genetic mutations; mutational driver status can substantially impact prognosis and diagnosis. Treatment goals for patients with MPNs focus on mitigating such long-term risks as vascular events and premature mortality, but also on minimizing disease burden and morbidity. This is a particularly important goal for those individuals with highly symptomatic disease.

Advances in the understanding of the pathobiology of MPNs resulted in the development of approaches that target the JAK/STAT signaling pathway, and the subsequent approval of a JAK1/JAK2 inhibitor. Novel strategies to manage MPNs remain a major focus of late-stage clinical trial evaluation. In fact, treatment paradigms promise to continue evolving in the near future in parallel with improved knowledge of how to practically apply biomarkers and manage treatment-related toxicities, and with the emergence of novel targeted compounds and combination approaches that are in various stages of clinical development.

This exciting, interactive, symposium will feature leading experts in the management of MPNs, and will assist practitioners in optimizing outcomes for their patients. The meeting will focus on methods to optimize the efficacy and safety of current management strategies, as well as new potentially practice-changing approaches that may further advance the field, which are currently being evaluated in clinical trials.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of hematological disorders. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hematological disorders will be invited to participate.

Educational Objectives:

Upon completion of this activity, participants will be able to:

  1. Explain mechanistic approaches to manage myeloproliferative neoplasms and their biologic rationale
  2. Discuss phenotypic drivers of myeloproliferative neoplasms and the implications for practice of new markers and diagnostic criteria
  3. Evaluate emerging clinical data regarding new agents and evolving strategies for myeloproliferative neoplasms
  4. Apply an evidence-based approach to optimize outcomes in the treatment of myeloproliferative neoplasms

Program Chair

Ruben A. Mesa, MD, FACP
Chair, Division of Hematology & Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Professor of Medicine
Phoenix, AZ

Become a Member

Forgot Password?
Calendar of Events
Filter By